[en] In diabetic patients, the use of drug-eluting stents (paclitaxel-PES or sirolimus-SES) reduces the risk of restenosis as compared to bare-metal stents. However, the risk of (very) late thrombosis is higher with drug-eluting stents than with bare-metal stents. All together, the incidence of major cardiovascular events is reduced with drug-eluting stents, mainly resulting from a diminution of revascularisation procedures rather than from a reduction in myocardial infarcts or cardiovascular deaths. Attempts to compare SES and PES gave discordant results in both randomised trials and registries. Efficacious antiplatelet therapy in the long run is mandatory in all diabetic patients treated with drug-eluting stents.
Disciplines :
Cardiovascular & respiratory systems Endocrinology, metabolism & nutrition
Author, co-author :
Nyssen, Astrid ; Université de Liège - ULiège > 3 doc medecine
Legrand, Victor ; Centre Hospitalier Universitaire de Liège - CHU > Cardiologie
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
Endoprotheses coronaires pharmaco-actives chez les patients diabetiques.
Alternative titles :
[en] Coronary drug-eluting stents in diabetic patients
Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes part II: Recent advances in coronary revascularisation. J Am Coll Cardiol 2007;49:643-56.
Stone KE, Chiquette E, Chilton RJ. Diabetic endovascular disease: Role of coronary artery revascularization. Am J Cardiol 2007;99(Suppl.):105B-12.
Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 2004;27:990-4.
Pagnotta P, Cabbavale M, Briguori C. How to treat diabetic patients with multivesseal disease in the DES era. Minerva Cardioangiol 2006;54:557-96.
* Legrand V. Therapy insight: Diabetes and drug-eluting stents. Nature Clin Pract 2007;4:143-50.
Scheen AJ, Warzée F. Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries (Letter). Diabetes Care 2004;27:1840-1.
Scheen AJ, Warzée F, Legrand V. Drug-eluting stents: Meta-analysis in diabetic patients (Letter). Eur Heart J 2004;25:2167-8.
* Boyden TF, Nallamothu BK, Moscucci M, et al. Meta-analysis of randomized trials of drug-eluting stents vs bare metal stents in patients with diabetes mellitus. Am J Cardiol 2007;99:1399-402.
Maresta A, Varani E, Balducelli M, et al. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian multicenter randomized DESSERT study). Am J Cardiol 2008;101:1560-6.
Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-etuting stents. JAMA 2005;293:2126-30.
Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-97.
Kirtane AJ, Ellis, SG, Dawkins KD, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus. Pooled analysis from 5 randomized trials. J Am Coll Cardiol 2008;51:708-15.
* Daemen J, Garcia-Garcia HM, Kukreja N, et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007;28:26-32.
Ortolani P, Balducelli M, Marzaroli P, et al. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions. Results from a real-world multicenter registry. Circulation 2008;117:923-30.
Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients. J Am Coll Cardiol 2007;50:501-8.
Stettler C, Allemann S, Egger M, et al. Efficacy of drug eluting stents in patients with and without diabetes mellitus : Indirect comparison of controlled trials. Heart 2006;92:650-7.
Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70.
Tomai F, Reimers B, De Luca L, et al. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions. Diabetes Care 2008;31:15-9.
Ong ATL, Aoki J, Van Mieghem CAG, et al. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- vs paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol 2005;96:358-62.
Kuchulakanti PK, Chu WW, Torguson R, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 2006;98:187-92.
Buch AN, Javaid A, Steinberg DH, et al. Outcomes after sirolimus- and paclitaxel-eluting stent implantation in patients with insulin-treated diabetes mellitus. Am J Cardiol 2008;101:1253-8.
Morice MC, Colombo A, Meier B, et al. Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions. The REALITY trial : A randomized controlled trial. JAMA 2006;295:895-904.
* Kumbhani DJ, Bavry AA, Kamdar AR, Helton TJ, Bhatt DL. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: Insights from randomized clinical trials. Am Heart J 2008;155:640-7.
Scheen AJ, Legrand D. Platelet dysfunction associated to insulin therapy in patients with type 2 diabetes: Please do not throw the baby out with the bath water (Letter). J Am Coll Cardiol 2007;49:628.